SUMMARY
Tissue-resident memory T cells (TRMs) in mice mediate optimal protective immunity to infection and vaccination, while in humans, the existence and properties of TRMs remain unclear. Here, we use a unique human tissue resource to determine whether human tissue memory T cells constitute a distinct subset in diverse mucosal and lymphoid tissues. We identify a core transcriptional profile within the CD69 + subset of memory CD4 + and CD8 + T cells in lung and spleen that is distinct from that of CD69 À TEM cells in tissues and circulation and defines human TRMs based on homology to the transcriptional profile of mouse CD8 + TRMs. Human TRMs in diverse sites exhibit increased expression of adhesion and inhibitory molecules, produce both pro-inflammatory and regulatory cytokines, and have reduced turnover compared with circulating TEM, suggesting unique adaptations for in situ immunity. Together, our results provide a unifying signature for human TRM and a blueprint for designing tissue-targeted immunotherapies.
INTRODUCTION
The establishment and maintenance of long-term immunity depends on the generation of memory T cells that can populate diverse tissue sites. The effector-memory (TEM) subset (Sallusto et al., 1999) is the predominant subset migrating through multiple tissues (Masopust et al., 2001 ); however, a significant fraction of TEM-phenotype cells persist as non-circulating subsets of tissue-resident memory T cells (TRMs) in multiple sites, including lungs, intestines, skin, liver, brain, and other mucosal surfaces (for reviews, see Mueller and Mackay, 2016; Schenkel and Masopust, 2014; Thome and Farber, 2015) . TRMs mediate optimal protective responses to site-specific infections through rapid mobilization of immune responses in situ (Schenkel et al., 2014a; Teijaro et al., 2011) . Mouse models have also demonstrated the feasibility of targeting TRMs in vaccines for generating protective immunity (Shin and Iwasaki, 2012; Zens et al., 2016) . Given their potential importance in immune protection and tissue homeostasis, an understanding of TRM identity, function, and regulation in humans is essential for translating strategies to target tissue-specific responses for protection and immunomodulation.
Advances in human TRM biology are limited by the lack of assays to distinguish circulating and resident memory T cells in tissues. In mice, tissue retention demonstrated by parabiosis (Jiang et al., 2012; Steinert et al., 2015) and in vivo antibody labeling (Anderson et al., 2014; Turner et al., 2014) identified phenotypic markers associated with tissue residence, including CD69 and CD103. In mice, CD69 is expressed by the majority of CD4 + and CD8 + TRMs in multiple sites (Jiang et al., 2012; Masopust et al., 2006; Schenkel et al., 2013; Teijaro et al., 2011) , while CD103 is only expressed by certain subsets of CD8 + TRM (Bergsbaken and Bevan, 2015; Mueller and Mackay, 2016) and not significantly by CD4 + TRM (Thom et al., 2015; Turner et al., 2014 ). CD69 has also been shown to have tissue-retention functions in lymph nodes through sequestration of the sphingosine-1-P receptor (S1PR) that mediates egress of T cells (Matloubian et al., 2004; Shiow et al., 2006) and is required for TRM retention in the skin (Mackay et al., 2015) . Whether CD69 can delineate TRMs from circulating TEM counterparts remains to be established in humans and is a critical outstanding question in the field.
In human tissues, we and others have identified and characterized TRM phenotype cells expressing CD69 and/or CD103 in multiple sites, including lungs, liver, lymphoid sites, skin, and intestines (Hombrink et al., 2016; Pallett et al., 2017; Purwar et al., 2011; Sathaliyawala et al., 2013; Thome and Farber, 2015 ; Thome et al., 2014; Watanabe et al., 2015; Wong et al., 2016; Woon et al., 2016) . However, it is not known whether TRMs represent a distinct subset in humans for both CD8 + and CD4 + T cell lineages, with unifying functional, phenotypic, and transcriptional signatures across tissues and individuals. We have established a human tissue resource to obtain blood and multiple lymphoid and mucosal tissues from previously healthy organ donors, enabling analysis of T cell compartmentalization and maintenance throughout life (Gordon et al., 2017; Sathaliyawala et al., 2013; Thome et al., 2014 Thome et al., , 2016a Thome et al., , 2016b (Figures 1A and 1B) . We focused on TEM cells as the major memory subset in tissues that is common to both CD4 + and CD8 + T cells as previously determined Figure 1C ). Previously, we also found maintenance of CD28 and CD127 expression by the majority of CD69 + tissue memory T cells, indicative of a quiescent state Figure 1D ; donor information is shown in Figures  2B and 2C ). The expression differences in these key genes were similar between three donors ( Figure 2C ). The genes differentially expressed by human CD69 + and CD69 À TEM cells ( Figure 2C ) included key molecules associated with mouse CD8 + TRMs from infection models (Mackay et al., 2013 Skon et al., 2013; Wakim et al., 2012) . Notably, downregulation of S1PR1 and its associated transcription factor KLF2 are required for CD8 + TRM establishment in mice (Skon et al., 2013) , and we found striking downregulation of S1PR1 (8-to 16-fold) and KLF2 (2-to 16-fold) transcripts for all CD69 + subsets compared with CD69 À subsets in every donor for both CD4 + and CD8 + T cells in lung and spleen ( Figure 2D ). In addition, human CD8 + CD69 + subsets exhibited upregulation of ITGAE (CD103), ITGA1 (CD49a), ICOS, and the transcription factor IRF4, which was also found to be upregulated by mouse CD8 + TRMs in different systems (Mackay and Kallies, 2017) . Together, these results show that the CD69 + tissue memory T cells constitute a transcriptionally distinct subset enriched for features of tissue residency.
We further compared the transcriptional profiles of tissue memory T cell subsets with circulating TEM cells isolated from the blood of three healthy volunteers. PCA using the gene signature in Figure 2C resulted in clustering of blood TEM with CD69 À tissue TEM, distinct from CD69 + samples, which clustered together ( Figure 2E ). By contrast, PCA using an equal number of randomly selected genes as a negative control yielded no clustering pattern ( Figure S1 ). This grouping suggests that CD69 expression by memory T cells in tissues distinguishes circulating memory subsets from those retained in tissues. 
(legend continued on next page)
A Core Gene Signature of Human CD69 + Memory T Cells Based on the gene expression analysis in Figure 2 , we identified 31 core genes with consistent significant differential expression by CD4 + and CD8 + CD69 + compared with the corresponding CD69 À subset from lung, spleen, and blood ( Figure 3A ; Table   S2 ). This core signature included upregulation of the adhesion markers ITGAE (CD103) and ITGA1 (CD49a); the chemokine receptors CXCR6 and CX3CR1; and molecules with known inhibitory functions in T cells, including PDCD1 (PD-1) , the dual-specificity phosphatase DUSP6 that turns off MAP kinase signaling (Bertin et al., 2015) , and interleukin (IL)-10. Downregulated genes within the core signature included S1PR1 and its associated transcription factor KLF2, which together control T cell homing and tissue retention (Skon et al., 2013) ; the related Kruppel-like transcription factor KLF3; and the lymph node homing receptor SELL (CD62L); as well as RAP1GAP1 and RGS1, G-protein-signaling genes that modulate T cell trafficking (Gibbons et al., 2011) . Pathways represented within the core signature include those controlling T cell adhesion and migration, proliferation, development, and activation (Table S3 ) that interconnect as diagrammed in Figure 3B . Many of the upregulated genes map downstream of T cell receptor (TCR) signaling, including CD69, adhesion molecules (ITGA1, ITGAE, and CRTAM), and activation-induced molecules IL-2, IL-10, and PD-1 that can regulate proliferation ( Figure 3B ). Differential upregulation or downregulation of specific chemokines and chemokine receptors (CXCL13, CXCR6, CX3CR1, SELL, and S1PR1) and modulation of G-protein-mediated signaling ( Figure 2B ) indicate that tissue residence involves specific tuning of migratory properties. Overall, these results establish that human CD69 + tissue memory T cells maintain a core signature impinging on multiple signaling pathways affecting cellular migration, function, and proliferation.
The relative transcript levels of key genes within the core gene signature ( To determine whether the core transcriptional profile common to CD69 + memory T cells in spleen and lungs defined a TRM signature, we compared the RNA-seq profile of the human tissue and blood subsets with that of mouse antigen-specific CD8 + TRMs isolated from skin and intestines following infection . PCA of whole transcriptomes shows species-specific transcriptional differences between human and mouse T cells dominating, with all human samples clustering together distinct from mouse TRM/TEM, and mouse samples forming distinct clusters based on the infection model ( Figure 4A , left (Wakim et al., 2012) and from mouse skin and lung (Mackay et al., 2013 ) ( Figure 4B ). Taken together, our results show that the gene signature of human CD69 + tissue memory T cells exhibits key features of TRMs and likely contain the human TRM subset.
A recent report showed that mouse CD8 + TRM in multiple tissues exhibit biased expression of the Hobit (homolog-of BLIMP in T cells) transcription factor, which can drive TRM differentiation in vivo . As Hobit was not part of the core gene set in our analysis, we specifically analyzed the expression level of Hobit (ZNF683) by human CD69 + memory T cells compared with mouse TRMs. In mouse TRMs, Hobit levels were higher than the housekeeping gene GAPDH and comparable to CD69 transcript levels. By contrast, for human CD69 + memory T cells, Hobit transcript levels were below median gene expression and significantly lower than GAPDH and CD69 levels ( Figure 4C ). These results suggest distinct molecular control of human and mouse TRM differentiation, despite similar core signatures. (E) PCA of CD69 + (red) and CD69 À (black indicates tissue; blue indicates blood) memory subsets based on the genes in (C). S, spleen; L, lung; B, blood.
See also Figure S1 and Table S6 . 2017) to extract TCR sequences from the RNA-seq reads (Supplemental Experimental Procedures). Between 0.1% and 0.3% of mapped reads could be assigned to the TCR region (data not shown), with detection of several hundred to over 1,000 unique clonotypes per sample ( Figure S4 ). From these data, we measured clonal diversity (number of unique clonotypes per TCR-mapped reads) and overlap between sites. Overall, CD69
À and CD69 + cells exhibited similar clonal diversity with CD4 + subsets maintaining higher clonal diversity compared to CD8 + memory subsets ( Figure 5A ), consistent with our previous findings showing increased clonality of memory CD8 + compared to CD4 + T cells from lymphoid sites Figures 2C and 3A) . IL-2 and IL-10 were produced by a consistently higher proportion of CD69 + compared with CD69 À memory T cells for both CD4 + and CD8 + subsets in spleen and lung ( Figures 5E and 5F ), consistent with increased IL2 and IL-10 transcription being part of the core signature ( Figure 3A) We applied a similar type of analysis as in Figure 6A to identify genes specific to lung or spleen memory T cells ( Figure 6B) Figure 6C ). These results indicate that CD101 could be an additional marker for CD8 + TRMs.
TRMs Are a Phenotypically Distinct Subset across Multiple Tissues
We asked whether multiple elements within the core signature together distinguished tissue memory subsets in spleen and lung using t-distributed scholastic neighbor embedding (t-SNE) analysis (van der Matten and Hinton, 2008; Wong et al., 2016) , a dimensionality reduction method used to visualize high-dimensional data in two dimensions so that cells expressing similar markers will be close to each other. Based on the expression of 6 markers defined as part of the core TRM signature (Figure 3 )-CD49a, CD103, CXCR6, CX3CR1, PD-1, and CD101-we found that CD69 + and CD69 À subsets were located in distinct regions of the t-SNE plots for both CD4 + and CD8 + T cells in each tissue ( Figure 7A ) and in density plots compiled from both sites ( Figure 7B , top). Manual gating within each dominant cluster revealed that CD69 À subsets exhibit elevated expression of CX3CR1 and low expression of CD49a, PD-1, CD101, and CXCR6 compared to CD4 + and CD8 + CD69 + subsets exhibiting high expression of CD49a, PD-1, and CXCR6 and low expression of CX3CR1, with CD8 + CD69 + subsets having coordinate expression of CD103 and CD101 ( Figure 7B ). These results further support the designation of tissue CD69 See also Figure S4 and Supplemental Experimental Procedures.
We assessed how multiple phenotypic properties of the core signature were distributed in diverse sites within an individual, including in intestines, mesenteric lymph nodes, tonsils, and blood in addition to lung and spleen ( Figures 7C, 7D , and S6). We initially generated t-SNE plots using concatenated data from all six tissue sites, revealing phenotypically distinct TEM and TRM subsets across multiple tissues ( Figure 7C ). In density plots, CD4 + and CD8 + TEM cells were localized to the same region of the t-SNE, suggesting that TEM phenotypes are conserved across lineages and tissues ( Figure 7C ). By contrast, CD8 + TRM and CD4 + TRMs appeared at different regions within the t-SNE density plots distinct from TEM cells ( Figure 7C ). Notably, there was a broader range of phenotypes based on these markers within the CD4 + TRM subset compared with the tighter clustering of CD8 + TRM phenotypes, suggesting increased heterogeneity of CD4 + tissue memory T cells. To compare the pattern of subset phenotypes between tissues, we assigned distinct colors to CD8 + TRM, CD4 + TRM, and TEM populations. Plotting all tissue samples on the same t-SNE reveals the localization of each cell population ( Figure 7D , left), with TEM cells and CD4 + and CD8 + TRMs maintaining their distinct clustering patterns and localization in each site (Figures 7D, right, and S6) . In blood, TEM cells clustered in a pattern similar to that of TEM in other tissues ( Figure 7D , right), providing additional evidence that TEM cells in tissues are circulating. Notably, CD8 + TRMs exhibit a focused clustering pattern in all tissues, suggesting that human TRMs represent a unique subset in multiple sites. CD4 + TRMs in all tissues exhibited a broader array of phenotypes, suggesting increased heterogeneity of CD4 + TRMs compared to CD8 + TRMs throughout the body.
DISCUSSION
In this study, we provide key insights into TRM biology through a comprehensive analysis of human CD4 + and CD8 + tissue memory subsets in lymphoid and mucosal tissues within and between multiple human donors. Our results establish that human tissue memory T cells fractionated based on CD69 expression exhibit a core signature of 31 genes conserved across tissues and lineages, with key homologies to the transcriptional profile of mouse TRMs. We demonstrate that human TRMs persist in multiple lymphoid, mucosal, and peripheral tissue sites; exist within both CD4 + and CD8 + lineages; and exhibit unique functional signatures, compared with circulating TEM cells, including proinflammatory and regulatory capacities and low turnover. Together, our results suggest that human TRMs are a distinct developmental subset uniquely adapted for in situ immunity. A definitive phenotypic marker for human TRMs has not previously been defined. Transcriptional profiling has been reported for mouse CD8 + TRMs in which CD8 + memory T cells isolated from a barrier site (skin, intestine, or lung) were compared with T cells from spleen (Mackay et al., 2013 . In human studies, CD8 + TRMs isolated based on CD103 expression from individual tissues (lung and skin) have been profiled in comparison to blood subsets (Cheuk et al., 2017; Hombrink et al., 2016) . Here, we used an innovative and comprehensive approach to assess differences in putative circulating and resident populations within tissues by directly comparing CD69 + memory subsets from a lymphoid and mucosal site (spleen and lung) with the corresponding CD69
À subset from each tissue, as well as CD69 À TEM from blood for both CD4 + and CD8 + lineages. While CD103 has been used to define CD8 + TRMs in mice (Schenkel and Masopust, 2014) and humans (Hombrink et al., 2016 ), our results demonstrate that CD69 expression can delineate tissue in determining tissue residence remains unclear. In mouse models, the majority of TRMs in barrier sites express CD69; however, TRMs lacking CD69 expression have been detected (Steinert et al., 2015) , and CD69 + cells in the thymus were shown to recirculate during homeostasis (Park et al., 2016) . However, the extent of CD69 expression by tissue memory T cells appears to be a function of antigen and pathogen exposure. We consistently find higher frequencies of CD69 expression by human tissue memory T cells compared to that found in mouse models maintained in specific pathogen free (spf) conditions, particularly in lymphoid sites (Teijaro et al., 2011; Thome et al., 2014) . Interestingly, T cells in ''dirty'' pet store mice had significantly higher frequencies of CD69 expression by T cells in tissues that was similar to those in humans (Beura et al., 2016) . In our results, we consistently see separation of transcriptional profiles between CD69 + and CD69 À subsets (Figure 2 ), suggesting that delineation between these subsets in humans may be more defined than in mouse spf models due to the history of antigen exposure.
The core TRM gene signature identified here includes canonical genes and proteins associated with tissue residence in mice, including downregulation of S1PR1, KLF2, and CD62L; upregulation of specific adhesion molecules (CD49a and CRTAM); modulation of specific chemokine receptors (increased CXCR6 and decreased CX3CR1); and upregulation of inhibitory or regulatory molecules (PD-1, DUSP6, and IL-10). We also found TRMs to exhibit a distinct functional profile encompassing pro-inflammatory, activating, and regulatory functions conserved between diverse individuals, tissues, and lineages. We further identified a marker, CD101, with immunomodulatory function that is expressed by CD8 + TRMs in multiple sites and could be useful in conjunction with other markers to identify TRMs. We found phenotypic heterogeneity based on the core markers, particularly among CD4 + TRMs, and additional tissue heterogeneity has been reported in CyTOF profiling of human tissue T cells (Wong et al., 2016) . CD103 expression by mouse intestinal TRMs (Bergsbaken and Bevan, 2015) and CD49a in human skin memory T cells (Cheuk et al., 2017) have been shown to delineate distinct functional capacities, and dissecting human TRM heterogeneity will be an important area of focus in future studies.
The dominant presence of TRMs in human tissues suggests a key protective role in situ. Our results reveal that human TRMs possess dichotomous functional capacities, not only being poised for enhanced production of IL-2 and pro-inflammatory cytokines but also producing IL-10 and exhibiting reduced proliferation and increased expression of inhibitors of T cell activation (i.e., PD-1 and CD101). This may enable the potent mobilization of immune responses in situ through pro-inflammatory cytokines but prevent excessive inflammation and cellular proliferation to limit inflammation-induced tissue damage. Moreover, the quiescent, inhibited state of TRMs as assessed by the low turnover could promote longevity and prevent inappropriate activation to non-pathogenic antigens to which many human tissues are continually exposed.
Our findings show that, in humans, TRMs exist in multiple tissue sites and within CD4 + and CD8 + T cell lineages. While TRMs have been detected in mouse lymph nodes (Schenkel et al., 2014b; Ugur et al., 2014) , the majority of mouse lymphoid memory CD4 + and CD8 + T cells in mice are circulating, particularly those in the spleen. The predominance of TRM-phenotype cells in all human lymphoid tissues examined here-including spleen, lymph nodes, and tonsils-may reflect their long-term persistence over decades and/or continual pathogen exposure, consistent with a recent study identifying memory T cells specific for persistent viruses in human tonsils (Woon et al., 2016) . TRM persistence in diverse sites may be due to the aggregate experience of numerous antigens over the human lifespan.
Interest in TRMs is rapidly expanding to the study of many diseases, from infection to cancer, to inflammation and autoimmunity. In humans, it is essential to identify and analyze these cells and determine whether they are functioning aberrantly in disease sites. Our study elucidates major unifying features of all tissue memory T cells in multiple healthy tissue sites within an individual. These results will serve as a valuable baseline from which to detect and study the role of tissue memory T cells in diseases and for promoting tissue immunity in vaccines as well as cell-and biologic-based immunotherapies.
EXPERIMENTAL PROCEDURES Acquisition of Tissue from Human Organ Donors
Human tissues were obtained from deceased organ donors at the time of organ acquisition for clinical transplantation through an approved research protocol and material transfer agreement (MTA) with LiveOnNY, the organ procurement organization for the New York metropolitan area. All donors were free of chronic disease, cancer, hepatitis B, and hepatitis C, and were HIV negative. Isolation of tissues from organ donors does not qualify as ''human subjects'' research, as confirmed by the Columbia University Institutional Review Board (IRB). For isolation of blood from living volunteers, blood was drawn via venipuncture from consented volunteers, as approved by the Columbia University IRB. A list of donors and individuals from whom samples were obtained for this study is presented in Table S1 .
Cell Isolation from Human Lymphoid and Non-lymphoid Tissues
Tissue samples were maintained in cold saline and brought to the laboratory within 2-4 hr of organ procurement. Spleen, lung, and intestinal samples were processed using enzymatic and mechanical digestion, resulting in high yields of live leukocytes, as described previously (Sathaliyawala et al., 2013; Thome et al., 2014) . Lymphocytes were isolated from blood samples using centrifugation through lymphocyte separation medium (Corning) for recovery of mononuclear cells.
Flow Cytometry Analysis and Cell Sorting
For flow cytometry analysis, single-cell suspensions were stained with fluorochrome-conjugated antibodies (see Table S4 for all antibodies used in this study) in staining buffer (PBS/1% fetal bovine serum/0.1% sodium azide). Intracellular staining was performed using the Fixation/Permeabilization Solution Kit (BD Biosciences) for the detection of cytokines and Foxp3/Transcription Factor Staining Buffer (eBioscience) for the detection of transcription factors. Control samples included unstained, single fluorochrome-stained compensation beads (UltraComp eBeads; eBioscience), and fluorescenceminus-one (FMO) controls. Stained cells were acquired using the BD LSR II or BD LSRFortessa. Data were analyzed using FlowJo software (Tree Star) and FCS Express (De Novo Software). FCS Express software was used for generating t-SNE plots. For isolation of subsets by fluorescence-activated cell sorting, lymphocyte suspensions were enriched for T cells using the MojoSort Human CD3 T Cell Isolation Kit (BioLegend), stained for surface markers as indicated, and sorted using the BD Influx high-speed cell sorter (BD Biosciences). + and CD69 À subsets, based on the gating strategy in Figure S1 , from the spleen and lung tissue of three individual donors (D226, D233, and D250; see Table S1 ), and CD4 + and CD8 + TEM cells (CD45RA À CCR7 À CD69 À ) were sorted from peripheral blood. RNA was isolated from cell pellets using the RNeasy Mini Kit (QIAGEN) and quantitated using an Agilent 2100 Bioanalyzer (Agilent Technologies), and library preparation and RNA-seq was performed by the Columbia Genome Center. Differential gene expression analysis was performed with EdgeR (Robinson et al., 2010) , and pathway analysis was performed with Ingenuity Pathway Analysis software (IPA; QIAGEN). For GSEA with microarray data (Suá rez-Fariñ as et al., 2010), the absolute value of log 2 fold change between TRM and TEM cells was used to rank the genes on the x axis. For a detailed description of RNA-seq procedures and analyses, see Supplemental Experimental Procedures. For a quality control (QC) summary of RNA-seq samples, see Table S5 . Supernatants from a minimum of 3 wells were pooled for each donor, and cytokine secretion was measured using the BD Cytometric Bead Array (Human Th1/Th2/Th17 Cytokine Kit). For short-term stimulations, CD4 + or CD8 + T cells from spleen and lung tissues were stimulated with Phorbol myristate acetate (PMA) (50 ng/mL) + ionomycin (1 mg/mL) for 3 hr at 37 C in the presence of BD GolgiStop. Cytokine production was assessed by intracellular staining for cytokines as described earlier.
T Cell Stimulations and Cytokine Analysis

Statistical Analysis
Descriptive statistics (percent, mean, median, and SEM) were calculated for each cell subset and tissue using Prism (GraphPad software). Significant differences in subset frequencies, ratios, geometric mean fluorescence intensity (gMFI), and density were assessed using a paired t test.
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